SCHEMBL12196524

SCHEMBL12196524

CCOc1ccc(-c2ccc(C3CCC(OC(=O)C4CCC(c5ccc(C)c(F)c5F)CC4)CC3)c(F)c2F)c(F)c1F

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ GLA P06280 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ ALOX5AP P20292 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ PDE10A Q9Y233 1/20 0.33
▸ FPR2 P25090 1/20 0.32
▸ FFAR4 Q5NUL3 1/20 0.32
▸ ABL1 P00519 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ HTT P42858 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ PTGS2 P35354 1/20 0.31
▸ ACACB O00763 1/20 0.31
▸ PTGDR2 Q9Y5Y4 1/20 0.31
▸ RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12196535 1.00 SMN1; SMN2 (0.36) SMN1; SMN2GLAHPGDMAPTALOX5AP
SCHEMBL10091362 0.96 SMN1; SMN2 (0.38) SMN1; SMN2GLAHPGDMAPTPDE10A
SCHEMBL14922599 0.95 SMN1; SMN2 (0.39) SMN1; SMN2GLAHPGDMAPTALOX5AP
SCHEMBL14922583 0.95 SMN1; SMN2 (0.39) SMN1; SMN2GLAHPGDMAPTALOX5AP
SCHEMBL12197461 0.93 SMN1; SMN2 (0.36) SMN1; SMN2GLAHPGDMAPTMEN1
SCHEMBL12197476 0.93 SMN1; SMN2 (0.36) SMN1; SMN2GLAHPGDMAPTMEN1
SCHEMBL12197231 0.92 SCN9A (0.36) SMN1; SMN2ALOX5APFEN1PDE10AFPR2
SCHEMBL12197353 0.92 SCN9A (0.36) SMN1; SMN2ALOX5APFEN1PDE10AFPR2
SCHEMBL12197225 0.92 FFAR4 (0.33) SMN1; SMN2GLAHPGDMAPTALOX5AP
SCHEMBL12197347 0.92 FFAR4 (0.33) SMN1; SMN2GLAHPGDMAPTALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8435422-B2 Five-ring compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2013-05-07 — — US disclosed
US-20110240919-A1 FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2011-10-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110240919-A1 FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE NCAPD3, CCND3, ZKSCAN2 SMN1; SMN2 3764/4885GLA 3232/4885HPGD 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback